Galectin Therapeutics, Inc. (GALT)
3.90
+0.14
(+3.72%)
USD |
NASDAQ |
Oct 02, 16:00
3.85
-0.05
(-1.28%)
After-Hours: 20:00
Galectin Therapeutics Enterprise Value : 385.31M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 385.31M |
| October 01, 2026 | 376.03M |
| September 30, 2026 | 383.99M |
| September 29, 2026 | 385.97M |
| September 28, 2026 | 387.30M |
| September 25, 2026 | 385.31M |
| September 24, 2026 | 389.29M |
| September 23, 2026 | 395.26M |
| September 22, 2026 | 401.23M |
| September 21, 2026 | 389.29M |
| September 18, 2026 | 384.65M |
| September 17, 2026 | 372.71M |
| September 16, 2026 | 370.72M |
| September 15, 2026 | 374.04M |
| September 14, 2026 | 381.33M |
| September 11, 2026 | 385.97M |
| September 10, 2026 | 385.31M |
| September 09, 2026 | 395.26M |
| September 08, 2026 | 401.23M |
| September 04, 2026 | 432.39M |
| September 03, 2026 | 415.15M |
| September 02, 2026 | 423.77M |
| September 01, 2026 | 403.22M |
| August 31, 2026 | 388.63M |
| August 28, 2026 | 393.27M |
| Date | Value |
|---|---|
| August 27, 2026 | 401.23M |
| August 26, 2026 | 401.89M |
| August 25, 2026 | 391.28M |
| August 24, 2026 | 383.99M |
| August 21, 2026 | 370.72M |
| August 20, 2026 | 363.43M |
| August 19, 2026 | 370.06M |
| August 18, 2026 | 360.11M |
| August 17, 2026 | 359.45M |
| August 14, 2026 | 354.81M |
| August 13, 2026 | 360.78M |
| August 12, 2026 | 334.91M |
| August 11, 2026 | 334.25M |
| August 10, 2026 | 333.59M |
| August 07, 2026 | 355.47M |
| August 06, 2026 | 340.22M |
| August 05, 2026 | 331.60M |
| August 04, 2026 | 324.64M |
| August 03, 2026 | 327.62M |
| July 31, 2026 | 323.64M |
| July 30, 2026 | 340.88M |
| July 29, 2026 | 358.12M |
| July 28, 2026 | 351.49M |
| July 27, 2026 | 350.83M |
| July 24, 2026 | 356.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Mirum Pharmaceuticals, Inc. | 5.695B |
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.113M |
| Total Expenses (Quarterly) | 9.113M |
| EPS Diluted (Quarterly) | -0.1393 |
| Earnings Yield | -11.02% |
| Normalized Earnings Yield | -9.749 |